Form 4: Hookipa Pharma Director Acquires 9,800 Stock Options

Director Sean A. Cassidy acquired 9,800 stock options in Hookipa Pharma Inc. on July 22, 2024.

Summary

• On July 22, 2024, Sean A. Cassidy, a director of Hookipa Pharma Inc., acquired 9,800 stock options.
• The exercise price of these options is $6.44.
• The options vest in 36 equal monthly installments starting July 22, 2024, contingent upon continuous service.
• The options expire on July 22, 2034.
• Following the transaction, Cassidy directly owns 9,800 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The acquisition of stock options by a director could be interpreted as a mildly positive signal, suggesting confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry as a form of compensation and incentive.
• The vesting schedule of 36 months is fairly standard.
• Comparable companies such as Moderna or BioNTech also utilize stock options as part of their executive compensation packages.

Key Dates